Recurrent Thyroid Gland Carcinoma Clinical Trial
Official title:
Radiofrequency Ablation Use in Thyroid Nodule
This phase IV trial studies the effect of radiofrequency ablation in treating patients with benign or low risk thyroid nodule. Radiofrequency ablation uses a needle to deliver a high-frequency electric current to kill tumor cells by heating them. The goal of this research study is to learn if ultrasound guided radiofrequency ablation can provide the same treatment result as standard surgical removal of the thyroid nodule, small primary thyroid, or thyroid cancers that have come back. Researchers also want to learn if the procedure can be less invasive and perhaps provide a better recovery response than surgery.
PRIMARY OBJECTIVE: I. Evaluate the longitudinal thyroid nodule volume changes induced by radiofrequency ablation (RFA) during post procedure follow-up. SECONDARY OBJECTIVES: I. Evaluate treatment response to compressive and/or cosmetic symptoms that affect patient's quality of life. II. Evaluate the sonographic features of the nodule induced by RFA. III. Compare cost of ultrasound guided RFA to gold standard surgical thyroidectomy. OUTLINE: Patients undergo ultrasound guided RFA over 1-2 hours. After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
| Completed |
NCT01709435 -
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01811212 -
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02393690 -
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
| Recruiting |
NCT04759911 -
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT00625846 -
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT00559949 -
AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
|
Phase 2 | |
| Active, not recruiting |
NCT00381641 -
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT00729157 -
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT02465060 -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT02152995 -
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
|
Phase 2 |